Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer

Lidia Moyano-Galceran; Elina A. Pietila; S. Pauliina Turunen; Sara Corvigno; Elisabet Hjerpe; Daria Bulanova; Ulrika Joneborg; Twana Alkasalias; Yuichiro Miki; Masakazu Yashiro; Anastasiya Chernenko; Joonas Jukonen; Madhurendra Singh; Hanna Dahlstrand; Joseph W. Carlson; Kaisa Lehti

doi:10.15252/emmm.201911177

Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer

Lidia Moyano-Galceran, Elina A. Pietila, S. Pauliina Turunen, Sara Corvigno, Elisabet Hjerpe, Daria Bulanova, Ulrika Joneborg, Twana Alkasalias, Yuichiro Miki, Masakazu Yashiro, Anastasiya Chernenko, Joonas Jukonen, Madhurendra Singh, Hanna Dahlstrand, Joseph W. Carlson, Kaisa Lehti

Research output: Contribution to journal › Article › Scientific › peer-review

Original language	English
Article number	11177
Journal	EMBO molecular medicine
Volume	12
Issue number	4
Number of pages	22
ISSN	1757-4676
DOIs	https://doi.org/10.15252/emmm.201911177
Publication status	Published - Apr 2020
MoE publication type	A1 Journal article-refereed

Fields of Science

chemotherapy
EphA2
GPRC5A
HGSC
resistance
TO-MESENCHYMAL TRANSITION
1ST-LINE TREATMENT
TUMOR-SUPPRESSOR
BREAST-CANCER
DOUBLE-BLIND
EPHA2
INVASION
HETEROGENEITY
METASTASIS
MECHANISMS
3122 Cancers

Access to Document

10.15252/emmm.201911177

emmm.201911177Final published version, 4.44 MBLicence: CC BY

Cite this

Moyano-Galceran, L., Pietila, E. A., Turunen, S. P., Corvigno, S., Hjerpe, E., Bulanova, D., Joneborg, U., Alkasalias, T., Miki, Y., Yashiro, M., Chernenko, A., Jukonen, J., Singh, M., Dahlstrand, H., Carlson, J. W., & Lehti, K. (2020). Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer. EMBO molecular medicine, 12(4), Article 11177. https://doi.org/10.15252/emmm.201911177

@article{180f85bcb98146b9a49d1ceccc819ebb,

title = "Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer",

keywords = "chemotherapy, EphA2, GPRC5A, HGSC, resistance, TO-MESENCHYMAL TRANSITION, 1ST-LINE TREATMENT, TUMOR-SUPPRESSOR, BREAST-CANCER, DOUBLE-BLIND, EPHA2, INVASION, HETEROGENEITY, METASTASIS, MECHANISMS, 3122 Cancers",

author = "Lidia Moyano-Galceran and Pietila, {Elina A.} and Turunen, {S. Pauliina} and Sara Corvigno and Elisabet Hjerpe and Daria Bulanova and Ulrika Joneborg and Twana Alkasalias and Yuichiro Miki and Masakazu Yashiro and Anastasiya Chernenko and Joonas Jukonen and Madhurendra Singh and Hanna Dahlstrand and Carlson, {Joseph W.} and Kaisa Lehti",

year = "2020",

month = apr,

doi = "10.15252/emmm.201911177",

language = "English",

volume = "12",

journal = "EMBO molecular medicine",

issn = "1757-4676",

publisher = "Wiley",

number = "4",

}

Moyano-Galceran, L, Pietila, EA, Turunen, SP, Corvigno, S, Hjerpe, E, Bulanova, D, Joneborg, U, Alkasalias, T, Miki, Y, Yashiro, M, Chernenko, A , Jukonen, J, Singh, M, Dahlstrand, H, Carlson, JW & Lehti, K 2020, 'Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer', EMBO molecular medicine, vol. 12, no. 4, 11177. https://doi.org/10.15252/emmm.201911177

TY - JOUR

T1 - Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer

AU - Moyano-Galceran, Lidia

AU - Pietila, Elina A.

AU - Turunen, S. Pauliina

AU - Corvigno, Sara

AU - Hjerpe, Elisabet

AU - Bulanova, Daria

AU - Joneborg, Ulrika

AU - Alkasalias, Twana

AU - Miki, Yuichiro

AU - Yashiro, Masakazu

AU - Chernenko, Anastasiya

AU - Jukonen, Joonas

AU - Singh, Madhurendra

AU - Dahlstrand, Hanna

AU - Carlson, Joseph W.

AU - Lehti, Kaisa

PY - 2020/4

Y1 - 2020/4

KW - chemotherapy

KW - EphA2

KW - GPRC5A

KW - HGSC

KW - resistance

KW - TO-MESENCHYMAL TRANSITION

KW - 1ST-LINE TREATMENT

KW - TUMOR-SUPPRESSOR

KW - BREAST-CANCER

KW - DOUBLE-BLIND

KW - EPHA2

KW - INVASION

KW - HETEROGENEITY

KW - METASTASIS

KW - MECHANISMS

KW - 3122 Cancers

U2 - 10.15252/emmm.201911177

DO - 10.15252/emmm.201911177

M3 - Article

SN - 1757-4676

VL - 12

JO - EMBO molecular medicine

JF - EMBO molecular medicine

IS - 4

M1 - 11177

ER -